Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) FCF Margin (2022 - 2025)

Stoke Therapeutics has reported FCF Margin over the past 4 years, most recently at 2213.41% for Q4 2025.

  • Quarterly results put FCF Margin at 2213.41% for Q4 2025, down 211063.0% from a year ago — trailing twelve months through Dec 2025 was 24.35% (up 26211.0% YoY), and the annual figure for FY2025 was 24.35%, up 26211.0%.
  • FCF Margin for Q4 2025 was 2213.41% at Stoke Therapeutics, down from 286.0% in the prior quarter.
  • Over the last five years, FCF Margin for STOK hit a ceiling of 1073.0% in Q1 2022 and a floor of 2213.41% in Q4 2025.
  • Median FCF Margin over the past 4 years was 487.05% (2024), compared with a mean of 488.05%.
  • Peak annual rise in FCF Margin hit 66609bps in 2025, while the deepest fall reached -211063bps in 2025.
  • Stoke Therapeutics' FCF Margin stood at 697.12% in 2022, then fell by -7bps to 745.11% in 2023, then skyrocketed by 86bps to 102.78% in 2024, then plummeted by -2054bps to 2213.41% in 2025.
  • The last three reported values for FCF Margin were 2213.41% (Q4 2025), 286.0% (Q3 2025), and 184.16% (Q2 2025) per Business Quant data.